Cantor Fitzgerald, L. P. Larimar Therapeutics, Inc. Transaction History
Cantor Fitzgerald, L. P.
- $8.4 Billion
- Q3 2025
A detailed history of Cantor Fitzgerald, L. P. transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 127,500 shares of LRMR stock, worth $430,950. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127,500
Previous 127,500
-0.0%
Holding current value
$430,950
Previous $411,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding LRMR
# of Institutions
155Shares Held
89MCall Options Held
6.44MPut Options Held
622K-
Deerfield Management Company, L.P. (Series C) New York, NY30.6MShares$103 Million1.84% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$20.4 Million0.34% of portfolio
-
Blue Owl Capital Holdings LP New York, NY5.85MShares$19.8 Million8.2% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.9MShares$16.6 Million0.01% of portfolio
-
Opaleye Management Inc. Boston, MA3.72MShares$12.6 Million2.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $146M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...